My 3 Top Biopharma Stock Picks for 2022
Thanks to the dual headwinds of sky-high inflation and the threat of rising interest rates, biopharmaceutical stocks appear poised for a turbulent 2022. Underscoring this point, investors have been dumping risky clinical and early commercial-stage biopharma stocks over the past several weeks in response to these closely intertwined macro variables.
This year thus seems destined to be a bona fide "stock-picker's market" for biopharma investors. With these key macroeconomic headwinds in mind, here are my top three biopharma stock picks for calendar year 2022.
Source Fool.com